These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38428724)

  • 1. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb.
    Zhang Z; Yang N; Lu H; Chen Y; Xu L; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhang W; Yang H; Peng X; Zhou L; Tong A
    Cancer Lett; 2024 Apr; 588():216760. PubMed ID: 38428724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells.
    Jin J; Wang R; Yang J; Hu H; Wang D; Cai L; Fang Z; Dong S; Hu S; Wang Y; Liu B
    Hum Gene Ther; 2022 Jun; 33(11-12):649-663. PubMed ID: 35272497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
    Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer.
    Hu Z; Li Y; Yang J; Liu J; Zhou H; Sun C; Tian C; Zhu C; Shao M; Wang S; Wei L; Liu M; Li S; Wang J; Xu H; Zhu W; Li X; Li J
    Sci Rep; 2024 Oct; 14(1):23671. PubMed ID: 39389985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy.
    Ravirala D; Mistretta B; Gunaratne PH; Pei G; Zhao Z; Zhang X
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody.
    Tian C; Liu J; Zhou H; Li J; Sun C; Zhu W; Yin Y; Li X
    Cancer Lett; 2021 Oct; 518():49-58. PubMed ID: 34139284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
    Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
    Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
    Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy.
    Deng X; Shen Y; Yi M; Zhang C; Zhao B; Zhong G; WeiyangLou ; Xue D; Leng Q; Ding J; Zhao R; Jia W; Dong C; Dai Z
    J Med Virol; 2023 May; 95(5):e28768. PubMed ID: 37212336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.
    Workenhe ST; Simmons G; Pol JG; Lichty BD; Halford WP; Mossman KL
    Mol Ther; 2014 Jan; 22(1):123-31. PubMed ID: 24343053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient Strategy for Synthesizing Vector-Free and Oncolytic Herpes Simplex Type 1 Viruses.
    Xiao H; Hu H; Guo Y; Li J; Zeng WB; Luo MH; Wang M; Hu Z
    ACS Synth Biol; 2024 Oct; 13(10):3268-3280. PubMed ID: 39358309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA.
    Boscheinen JB; Thomann S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Dörrie J; Schaft N; Bach C; Rohrhofer A; Werner-Klein M; Schmidt B; Schuster P
    Front Immunol; 2019; 10():2. PubMed ID: 30723467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies.
    Ishino R; Kawase Y; Kitawaki T; Sugimoto N; Oku M; Uchida S; Imataki O; Matsuoka A; Taoka T; Kawakami K; van Kuppevelt TH; Todo T; Takaori-Kondo A; Kadowaki N
    Mol Ther; 2021 Feb; 29(2):762-774. PubMed ID: 33038943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic α-herpesvirus and myeloid-tropic cytomegalovirus cooperatively enhance systemic antitumor responses.
    Jiang H; Nace R; Ariail E; Ma Y; McGlinch E; Ferguson C; Fernandez Carrasco T; Packiriswamy N; Zhang L; Peng KW; Russell SJ
    Mol Ther; 2024 Jan; 32(1):241-256. PubMed ID: 37927036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oncolytic HSV-1 armed with Visfatin enhances antitumor effects by remodeling tumor microenvironment against murine pancreatic cancer.
    Zhao J; Wang H; Chen J; Wang C; Gong N; Zhou F; Li X; Cao Y; Zhang H; Wang W; Zheng H; Zhang C
    Biochem Biophys Res Commun; 2024 Jul; 718():149931. PubMed ID: 38723415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma.
    Reale A; Gatta A; Shaik AKB; Shallak M; Chiaravalli AM; Cerati M; Zaccaria M; La Rosa S; Calistri A; Accolla RS; Forlani G
    J Transl Med; 2024 Sep; 22(1):862. PubMed ID: 39334370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
    Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
    Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.